Introduction:
The incidence of brain metastases and the spectrum of metastasizing primary cancers vary with patient's age 1 . Brain metastases occur more frequently in adults than in children 2 . Among adults, the highest incidence is observed in the fifth to seventh decades of life 3 . The most common sources of brain metastases in this group of patients were cancers of the lungs, breasts, and skin in descending order. In children, the most common cause of brain metastases is leukaemia, followed by lymphoma 4 .
The overall incidence of brain metastases is not affected by patient's gender, nor the incidence of brain metastases from a given primary cancer. The only apparent exception to this is melanoma, which is more likely to spread to the brain in male patients 5 . Lung cancer is the most common source of brain metastases in men where as breast cancer is the most common source in women 6 .
The histological type of the primary tumour appears to be the major dictator of the frequency and pattern of intracranial spread. Lungs, breast cancer, melanoma, renal and colon cancers account for the majority of all brain metastases in order of decreasing relative frequency. Primary lung tumours account for 30 to 60% of all brain metastases cases 7 . Breast cancer ranks second contributing 10 to 30% of all brain metastases among women. Approximately 5 to 21% of patients with brain metastases have melanoma as the primary tumour. However, virtually any malignancy can metastasize to the brain. Patients with symptoms caused by a brain metastases varies 8 .
Treatment modalities of brain metastases are: (i) radiation therapy a. Dosefractionation schemes for whole brain radiation therapy b. altered fractionation schemes c. radiosensitizers d. prophylactic cranial irradiation for small cell lung cancer (ii) surgical resection (iii) postoperative whole brain radiation therapy (iv) stereotactic radiosurgery and (v) chemotherapy. Sometimes metastatic brain tumours are encountered where the primary scapes detection despite meticulous search by clinical and investigation method. Sometimes radiotherapy and chemotherapy are used in regulated combination 9 .
Materials and Methods:
This was study a prospective study carried out from February 2002 to December 2005. A structured questionnaire was made. Data were collected after patient's admission. MRI of brain with contrast revealed intracranial tumour, whose radiological features were strongly suspicious of being metastatic tumour, histopathological diagnosis were made from material harvested at brain biopsy or by FNAC of obvious primaries. Total 35 100 Table I shows that major proportion (60.00%) of the patients belonged to the age group of <60 years and the second height (31.43%) age group was 40-49 years. Only 5.7% was in the age of 20-39 years and 2.85% were in the age group of less than 20 years. Table III shows that the highest occupational group were day laborers (31.43%) followed by service-holders (22.85%) and farmers (20%). Table III shows that the commonest symptoms were headache (60%) followed by vomiting (40%) and convulsion (20%). Table IX shows that highest group of patients (42.86%) were treated by surgery+ radiotherapy followed by surgery + chemotherapy + Radiotherapy (40%) and Radiotherapy (14.29%) alone. Table -XI shows that heighest survival rate was 3 to 6 months (31.42%) followed by 6-9 months (28.57) and 9-12 months (20.00%). 
Results:

Discussion:
This was a prospective study. In this study the heighest age group was <60 years. In a previous study the heighest age groups were from fifth to seventh decade 10 . Among the clinical features most common was one sided weakness. Most of the primary sites were from lungs (60%). In a previous study the most common sources of brain metastases were cancers of the lung, breast and skin, in descending order 10 . In our study the commonest site of metastasis was frontal lobe (34.28%) and the most common histopathological type was adenocarcinoma (40.00%). Of patients with lung cancer, 18 to 65% developed brain metastasis and more than 40% of the patients had adenocarcinoma in a previous study 11 . In this study, treatment options were surgery, radiotherapy, chemotherapy, radioiodine-ablation etc. Sixty percent of the patients improve after treatment and survival rate was 3 to 6 months in 31.42% cases, 6 to 9 months in 28.57% cases, 9 to 12 months in 20.00% cases and more than 12 months were 8.57% cases. In a previous study median survival time of 1 year was in 30% of patients 12 .
Conclusion:
This study showed that commonest type of brain metastases was adenocarcinoma and primary site of lesion was lungs. Best option of treatment was surgery plus radiotherapy and median survival rate of 1 year was in 20.00% of cases.
